Supplementary Figure 2 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 | AMiner
Supplementary Figure 2 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 2. Concentration-time profiles of 3H-labeled mIAP301 and Coil-MMP-mIAP301 were profiled in the plasma, liver, and tumors of BALB/c mice bearing A20 lymphoma tumors once tumors reached approximately 250 mm3 in size.
原文链接
分享
引用
